Brandywine Global Investment Management Lowered By $1.41 Million Its Jazz Pharmaceuticals Plc (JAZZ) Position; Profile of 12 Analysts Covering Wright Medical Group (WMGI)

August 11, 2017 - By Adrian Mccoy

Brandywine Global Investment Management Llc decreased Jazz Pharmaceuticals Plc (JAZZ) stake by 5.2% reported in 2016Q4 SEC filing. Brandywine Global Investment Management Llc sold 12,900 shares as Jazz Pharmaceuticals Plc (JAZZ)’s stock rose 8.72%. The Brandywine Global Investment Management Llc holds 235,179 shares with $25.64M value, down from 248,079 last quarter. Jazz Pharmaceuticals Plc now has $8.63B valuation. The stock rose 0.14% or $0.2 reaching $142.91. About 472,611 shares traded or 8.56% up from the average. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has risen 1.25% since August 11, 2016 and is uptrending. It has underperformed by 15.45% the S&P500.

Among 16 analysts covering Wright Medical Group (NASDAQ:WMGI), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Wright Medical Group had 26 analyst reports since August 20, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Hold” on Thursday, August 3. The firm has “Hold” rating by Needham given on Wednesday, February 15. The rating was downgraded by Guggenheim to “Neutral” on Tuesday, January 3. The rating was upgraded by Jefferies on Monday, November 30 to “Buy”. Piper Jaffray maintained the shares of WMGI in report on Wednesday, August 2 with “Buy” rating. Northcoast upgraded the stock to “Buy” rating in Tuesday, March 21 report. The firm has “Buy” rating by Bank of America given on Monday, April 11. The rating was upgraded by JP Morgan to “Overweight” on Wednesday, July 13. On Tuesday, April 11 the stock rating was downgraded by Bank of America to “Neutral”. William Blair maintained the shares of WMGI in report on Sunday, September 6 with “Outperform” rating. See Wright Medical Group Inc (NASDAQ:WMGI) latest ratings:

02/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $34.0000 Maintain
03/08/2017 Broker: Needham Rating: Hold
03/08/2017 Broker: Oppenheimer Rating: Hold New Target: $30.0000 Maintain
29/06/2017 Broker: Jefferies Rating: Buy New Target: $33.0000 Maintain
30/06/2017 Broker: Cantor Fitzgerald Rating: Overweight New Target: $33 Initiates Coverage On
11/04/2017 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade
21/03/2017 Broker: Northcoast Old Rating: Neutral New Rating: Buy Upgrade
15/02/2017 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade

Wright Medical Group, Inc. is a global specialty orthopaedic company. The company has market cap of $1.43 billion. The Firm through Wright Medical Technology, Inc. and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients’ lifestyles. It currently has negative earnings. The Firm operates through three divisions: U.S., International and BioMimetic.

About 789,751 shares traded. Wright Medical Group Inc (NASDAQ:WMGI) has risen 49.62% since August 11, 2016 and is uptrending. It has outperformed by 32.92% the S&P500.

Investors sentiment decreased to 0.68 in Q4 2016. Its down 0.13, from 0.81 in 2016Q3. It dived, as 64 investors sold JAZZ shares while 111 reduced holdings. 43 funds opened positions while 76 raised stakes. 50.81 million shares or 3.20% less from 52.49 million shares in 2016Q3 were reported. Tekla Capital Management holds 331,411 shares or 1.54% of its portfolio. 255,865 are owned by D E Shaw. Orbimed Ltd has 0.52% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 371,400 shares. Gotham Asset Mgmt Limited Liability reported 81,417 shares. Moreover, Royal State Bank Of Canada has 0.04% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 634,717 shares. California Employees Retirement System stated it has 116,700 shares. Sumitomo Mitsui Asset Management Company Ltd, a Japan-based fund reported 4,203 shares. Credit Suisse Ag invested 0.01% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Columbus Circle has 0.19% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.01% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 12,913 shares. Amp Ltd has 0.02% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Dekabank Deutsche Girozentrale invested in 0.06% or 55,156 shares. Pennsylvania-based Peoples Finance Svcs Corp has invested 0% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). State Street holds 0.01% or 784,033 shares. Clarivest Asset Management Llc has 3,560 shares.

Since February 15, 2017, it had 0 buys, and 9 selling transactions for $7.73 million activity. $116,666 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) was sold by Treacy Paul. $30,596 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares were sold by MILLER MICHAEL PATRICK. The insider Hooper Suzanne Sawochka sold $400,000. $1.74M worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) was sold by WILSON KAREN J. Another trade for 30,000 shares valued at $4.60 million was made by COZADD BRUCE C on Thursday, May 11. $750,000 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) was sold by Winningham Rick E on Thursday, June 1.

Brandywine Global Investment Management Llc increased Tyson Foods Inc (NYSE:TSN) stake by 51,958 shares to 131,055 valued at $8.08 million in 2016Q4. It also upped Toll Brothers Inc (NYSE:TOL) stake by 508,032 shares and now owns 602,919 shares. Cisco Sys Inc (NASDAQ:CSCO) was raised too.

Among 17 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Jazz Pharmaceuticals had 36 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Market Perform” rating given on Wednesday, November 25 by Bernstein. The firm earned “Buy” rating on Wednesday, June 7 by Cowen & Co. The firm has “Outperform” rating given on Friday, February 19 by Wells Fargo. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Outperform” rating given on Wednesday, October 14 by Northland Capital. The firm has “Buy” rating by Mizuho given on Tuesday, February 21. The stock has “Buy” rating by Deutsche Bank on Monday, July 17. Piper Jaffray maintained the shares of JAZZ in report on Friday, July 14 with “Buy” rating. The rating was maintained by SunTrust with “Buy” on Thursday, June 2. Piper Jaffray maintained it with “Buy” rating and $17700 target in Tuesday, August 8 report. The rating was maintained by Mizuho with “Buy” on Wednesday, November 9.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>